Encouraging preclinical data foreground a clinical trial evaluating ruxolitinib (Jakafi) with selinexor (Xpovio) in patients with multiple myeloma, according to James R. Berenson, MD.
CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and chief executive officer of the Institute for Myeloma and Bone Cancer Research, and private practitioner in West Hollywood, California, about ongoing trials exploring JAK inhibitors in myeloma.